Stuart Chaffee, Ph.D.

Stuart Chaffee, PhD brings a wealth of experience including contributing to starting four publicly traded biotechnology companies, raising over $900M in private and public capital, and $4.9B in transactions.

Chaffee was most recently Chief Business Officer at Affinivax, Inc., until its sale to GlaxoSmithKline in May of 2022. Prior to his time at Affinivax, Chaffee was Chief Business Officer and Chief Financial Officer at Praxis Precision Medicines, a clinical-stage genetic neuroscience company, where he raised over $100 million in private equity to fund an innovative pipeline identifying candidates for the development of novel therapies for patients affected by central nervous system disorders. He also served as Entrepreneur in Residence with Atlas Venture, where he co-founded and served as Head of Business Operations at Kymera Therapeutics, a biopharmaceutical company, started from the concept of using the body’s innate protein degradation machinery to target previously untreatable diseases. In addition to early-stage company building, Stuart has spent time at Amgen in drug discovery and at Biogen in several corporate functions. He received his B.S. in Chemistry from the College of William and Mary, a Ph.D. in Synthetic Organic Chemistry from Yale University, and an MBA in Finance from the Wharton School at the University of Pennsylvania.